Future Medicines Institute in Northern Ireland Receives £55m Investment

An investment totaling £55m has been disclosed for a newly established institute, aimed at fostering innovation and enhancing productivity within the field of precision medicine across Northern Ireland. This new entity, named the Future Medicines Institute (FMI), is situated at Queen’s University Belfast (QUB) and benefits from the support of a consortium comprising prominent medical companies, alongside the participation of academics from Ulster University (UU). Within this collaborative laboratory environment, specialists from the medical, academic, and industrial sectors will unite their efforts. Their collective goal is to propel the local precision medicine sector forward and contribute to mitigating the “brain drain” phenomenon in Northern Ireland. Precision medicine is defined as a therapeutic approach where treatment strategies are customized to an individual patient’s specific requirements, taking into account their diagnosis, genetic profile, and lifestyle factors. Representing a pioneering initiative for Northern Ireland, the institute’s partners include companies like Almac and Randox. During the announcement of this multi-million pound investment, Economy Minister Conor Murphy stated that the new institute is expected to further develop Northern Ireland’s expanding diagnostic and therapeutic sector. Prof Christopher Scott, Dean of research at the Faculty of Medicine, Health and Life Sciences at QUB, commented that the institute would demonstrate Northern Ireland’s possession of a suitably trained workforce capable of guiding products from the research phase through to development. He further elaborated, stating: “We are treading new ground together with new equipment and expertise.” He added, “The overarching goal is to drive the productivity of research and development that we do in Northern Ireland. We want to make the process more accessible and de-risk the involvement of research and development for our companies. We want to create new jobs at a range of levels from higher apprenticeships, to PhDs and ensure that we develop those jobs in a way that they stay here in Northern Ireland and that we stop the brain drain and show Northern Ireland is a place to do business with.” Wendy Moore, representing Diaceutics, a company specializing in testing laboratories, expressed her dedication to advancing and safeguarding women’s health. She stated: “Being able to develop treatments targeting ovarian and breast cancer is crucial and that’s what we will do here in this lab and then share the data and knowledge eight our colleagues in America.” According to the project’s proponents, the institute is poised to establish the inaugural joint infrastructure for life and health sciences within Northern Ireland. They also noted that its operational model signifies a considerable deviation from conventional methods of conducting medical research. Characterized as a “rich and dynamic cluster” of collaborating entities, the institute is scheduled to commence operations in January. Prof Scott emphasized that the initiative’s core focus is on developing a product that will be manufactured and supplied in Northern Ireland for the benefit of individuals both within NI and globally.